Wednesday, May 1, 2019 Daily Archives

AAV, easy as M-A-b? CEVEC fundraiser to scale-up production

by

Germany’s CEVEC claims it can produce adeno-associated viral (AAV) vectors as easily as monoclonal antibodies (MAbs), and has raised funds to expand and commercialize its production platform. While the total raised from new and existing investors in the Series D financing has not been disclosed, Cologne, Germany-based CEVEC says it will be used to advance its CAP GT-based stable AAV vector production platform and move it towards commercialization. As more gene therapies enter the clinic, there is high demand for…

May 1, 2019

Seattle Genetics in ‘good shape’ after restoring Adcetris inventory

by

After suffering an $18 million inventory write off, Seattle Genetics says its business as usual for the manufacturing of its lead antibody-drug conjugate (ADC) Adcetris. In its fourth quarter 2018, Seattle Genetics reported an increase in its cost of sales attributed to an $18.1 million (€16.2 million) inventory write-off related to in-process production that did not meet manufacturing specifications and did not impact availability of product supply required to meet demand for its ADC product Adcetris (brentuximab vedotin). Three months…

May 1, 2019

Clearing the Way for Viral Clearance

by

This webcast features: David Cetlin, CEO, MockV Solutions and John Li, Staff Scientist, Thermo Fisher Scientific To determine the viral clearance efficacy of biomanufacturing steps, mammalian viruses are “spiked†into in-process solutions, processed and analysed for reduction. Due to the infectious nature of these live viruses, “spiking studies†are typically conducted in specialized BSL-2 facilities. The costs and logistics associated limit viral clearance analysis during process development and characterization. To overcome this challenge, a non-infectious Minute Virus of Mice –…

May 1, 2019

Cell Culture Bioprocessing in Perfusion: Assessing Cell Retention Technologies

by , and

Upstream bioprocessing in perfusion mode holds great promise for industrial production of cells and biologics. In perfusion, fresh medium is added constantly to the bioreactor, and used medium is harvested while the cells are retained in the bioreactor. As a result, the composition of the cell culture medium stays quite constant during the process. This offers several advantages. In perfusion, higher cell densities can be reached than in batch and fed-batch processes, therefore enhancing volumetric productivity. Because medium composition can…

May 1, 2019

PureTech cites Big Pharma tech partnerships as 2018 highlights

by

PureTech Health says delivery technology deal with Roche was key part of its financial performance in 2018. The US biotech made the comments last week. It explained that its revenue growth for the year – $20.7 million (€18.5 million), up from $2.5 million in 2017 – was due in part to the Roche accord inked last July. CEO Daphne Zohar also predicted the deal will shape future performance. “We are now engaged in collaborative research with Roche to advance our…

May 1, 2019